The risk of a composite of major macrovascular and microvascu- lar events was reduced by 9% (HR, 0.91; 95% CI, 0.83 1.00; P=0.04), but there was no reduction in the incidence of major macrovascular events, including stroke. IntheAnglo-ScandinavianCardiacOutcomesTrial(ASCOT), the effects of 2 antihypertensive treatment strategies (amlodipine with the addition of perindopril as required [amlodipine-based] or atenolol with addition of thiazide as required [atenolol- based]) for the prevention of major cardiovascular events were compared in 5137 patients with diabetes mellitus.308 The target BP was <130/80 mmHg. The trial was terminated early because of reductions in mortality and stroke with the amlodipine-based regimen. In patients with diabetes mellitus, the amlodipine- based therapy reduced the incidence of total cardiovascular events and procedures compared with the atenolol-based regi- reduction (P=0.017) in fatal and nonfatal strokes. The open-label ACCORD trial randomized trial 4733 par- ticipants to 1 of 2 groups with different treatment goals: SBP <120 mmHg as the more intensive goal and SBP <140 mmHg as the less intensive goal. Randomization to the more intensive goal did not reduce the rate of the composite outcome of fatal and nonfatal major CVD events (HR, 0.88; 95% CI, 0.73 1.06; P=0.20). Stroke was a prespecified secondary end point occur- ring at annual rates of 0.32% (more intensive) and 0.53% (less In the Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, 11506 patients (6746 with diabetes mellitus) with hypertension were randomized to treatment with benazepril plus amlodipine or benazepril plus hydro- The primary end point was the composite of death resulting from CVD, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitated cardiac arrest, and cor- onary revascularization. 